Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7
暂无分享,去创建一个
Bowen Shi | Xiaoqian Zhang | Xiaocui Zheng | Jie Ding | Yongjiang Yu | Haojie Chen | Jia Luo | Haiying Ji | Kun Du | Shaojun Chen | Yujia Yin | Xiaocui Zheng
[1] Xuesong Li,et al. Upregulation of ATP Binding Cassette Subfamily C Member 5 facilitates Prostate Cancer progression and Enzalutamide resistance via the CDK1-mediated AR Ser81 Phosphorylation Pathway , 2021, International journal of biological sciences.
[2] Shouhong Gao,et al. Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer , 2021, Cancer cell international.
[3] A. Jemal,et al. Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[4] P. Nelson,et al. Role of androgen receptor splice variant 7 (AR-V7) in prostate cancer resistance to 2nd generation androgen receptor signaling inhibitors , 2020, Oncogene.
[5] H. Klocker,et al. Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer , 2020, Cancers.
[6] B. Dai,et al. Targeting CPT1B as a potential therapeutic strategy in castration‐resistant and enzalutamide‐resistant prostate cancer , 2020, The Prostate.
[7] Jinbao Liu,et al. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy , 2020, Theranostics.
[8] Ping Li,et al. Asatone and Isoasatone A Against Spodoptera litura Fab. by Acting on Cytochrome P450 Monoxygenases and Glutathione Transferases , 2019, Molecules.
[9] Y. Niu,et al. Restoration of FKBP51 protein promotes the progression of castration resistant prostate cancer. , 2019, Annals of translational medicine.
[10] Lang Li,et al. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer , 2019, The Journal of Biological Chemistry.
[11] M. Gleave,et al. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. , 2019, European urology.
[12] S. Kuang,et al. Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC) , 2018, The Journal of Biological Chemistry.
[13] Hongtuan Zhang,et al. Loss of miR-516a-3p mediates upregulation of ABCC5 in prostate cancer and drives its progression , 2018, OncoTargets and therapy.
[14] Joshua M. Stuart,et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer , 2018, Cell.
[15] Christopher W. Whelan,et al. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing , 2018, Cell.
[16] Zhihua Liu,et al. Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13 , 2018, Proceedings of the National Academy of Sciences.
[17] M. Gleave,et al. Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells , 2018, Proceedings of the National Academy of Sciences.
[18] E. Niskanen,et al. Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome , 2016, Nucleic acids research.
[19] F. Saad,et al. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. , 2016, European urology.
[20] R. Laing,et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.
[21] P. Borst,et al. ATP-binding Cassette Subfamily C Member 5 (ABCC5) Functions as an Efflux Transporter of Glutamate Conjugates and Analogs* , 2015, The Journal of Biological Chemistry.
[22] A. Schally,et al. New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones , 2015, Asian journal of andrology.
[23] Yezi Zhu,et al. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. , 2015, Cancer research.
[24] W. Isaacs,et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.
[25] J. Luo,et al. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects , 2014, Oncogene.
[26] Yezi Zhu,et al. Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.
[27] Chawnshang Chang,et al. Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death. , 2014, Cancer treatment reviews.
[28] S. Chowdhury,et al. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents. , 2014, Cancer treatment reviews.
[29] J. Bono,et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. , 2014, European journal of cancer.
[30] Zhifeng Dong,et al. ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone , 2012, Breast Cancer Research.
[31] K. V. Donkena,et al. Recent advances in understanding hormonal therapy resistant prostate cancer. , 2010, Current cancer drug targets.
[32] J. Fletcher,et al. ABC transporters in cancer: more than just drug efflux pumps , 2010, Nature Reviews Cancer.
[33] H. Scher,et al. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.
[34] R. Ueda,et al. The determinants of sensitivity and acquired resistance to gemcitabine differ in non–small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity , 2006, Molecular Cancer Therapeutics.
[35] C. Shimizu,et al. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients , 2006, Breast Cancer Research and Treatment.
[36] P. Johnston,et al. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites , 2005, Molecular Cancer Therapeutics.
[37] J. Willey,et al. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines , 2005, Molecular Cancer.
[38] Jorma Isola,et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.